



Positive results for Intercell's Japanese Encephalitis Vaccine in pivotal Phase III Safety trial

- » Results for Intercell's Japanese Encephalitis virus vaccine in the pivotal Phase III safety trial, which included 2,683 randomized subjects, are positive
- » Intercell's JE vaccine was well tolerated, no critical adverse events were observed
- » With these results, the preparations for the filing process with the United States Food and Drug Administration (FDA) are fully on track for an anticipated market launch in the United States in 2007

Vienna (Austria), August 24, 2006 - Intercell AG (VSE, "ICLL") announced today that the safety analyses for the pivotal Phase III safety trial of its investigational Japanese Encephalitis vaccine are positive.

The pivotal Phase III safety trial was conducted at 39 study sites in Austria, Germany, Romania, Israel, Australia, New Zealand and in the US, and included 2,683 randomized subjects. The study was designed to analyze the safety and tolerability of Intercell's investigational vaccine in a multicenter, multinational, double-blind, placebo-controlled randomized study.

Major endpoints of this study were the frequency of adverse events in both test groups, as well as local tolerability findings in both groups. First analyses of this trial show that Intercell's investigational Japanese Encephalitis vaccine was systemically and locally well tolerated. Overall, the local tolerability and general safety profile of the Intercell JE vaccine appeared to be comparable with placebo.

The Phase III clinical trial program consists of several additional clinical trials including a pivotal immunogenicity trial, a single shot trial, and a co-vaccination trial for travelers, which are all expected to be completed by early 2007. To date, more than 4,800 of the approximately 5,370 trial participants have been enrolled and vaccinated in these clinical trials. The pivotal Phase III clinical trial program is designed to meet regulatory requirements in the United States, Europe and Australia. Assuming approval by the regulatory authorities, the first market launch is anticipated for 2007. Preparations for the submission of a BLA (Biologics License Application) to the FDA have commenced.

Full clinical results of the pivotal immunogenicity trial are planned to be presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), November 12-16, Atlanta, and full clinical results of the pivotal safety trial are planned to be presented at the 10th Conference of the International Society of Travel Medicine, May 20-24, 2007 in Vancouver, Canada.

About Intercell's investigational JE vaccine

Intercell's novel investigational Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus. With over 3 billion people





living in endemic areas, Japanese Encephalitis, a mosquito-borne flaviviral infection, is the leading cause of childhood encephalitis and viral encephalitis in Asia.

In a former Phase II head-to-head comparison with the U.S. licensed product JE-VAX®, Intercell's investigational vaccine was shown to be:

- » Less reactogenic – both in frequency and intensity
- » More potent – higher antibody levels at all doses studied one month after the immunizations;
- » More convenient – 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization

Intercell's JE vaccine, manufactured in the Company's propriety manufacturing facility in Scotland, is novel as it is using tissue culture rather than live organisms and does not contain any stabilizers or preservatives in its formulation.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for prevention and treatment of infectious diseases for which there exists substantial unaddressed medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis AG, sanofi pasteur S.A., Merck&Co., Inc., the Statens Serum Institut and Kirin Brewery Co., Ltd. The Company has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.